5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 634-641

  Amar, Marcelo J A ^a   D'Souza, Wilissa ^b   Turner, Scott ^c   Demosky, Stephen ^a   Sviridov, Denis ^a   Stonik, John ^a   Luchoomun, Jayraz ^c   Voogt, Jason ^c   Hellerstein, Marc ^d,e   Sviridov, Dmitri ^b   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c KINEMED INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN 5A; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FECES; HEART PROTECTION; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; AORTA; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR MIMICRY; PEPTIDES; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77954930317     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167890     Document Type: Article

References (40)

1. Alam K, Meidell RS, and Spady DK (2001) Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J Biol Chem 276:15641-15649.
2. Amar MJ, Dugi KA, Haudenschild CC, Shamburek RD, Foger B, Chase M, Bensadoun A, Hoyt RF Jr, Brewer HB Jr, and Santamarina-Fojo S (1998) Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. J Lipid Res 39:2436-2442.
3. Baker PW, Rye KA, Gamble JR, Vadas MA, and Barter PJ (2000) Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 41:1261-1267.
4. Barter P (2009) Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 104:10E-15E.
5. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, and Azhar S (2010) A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res 51:1496-1503.
6. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, and Rader DJ (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49:1344-1352.
7. Buga GM, Navab M, Imaizumi S, Reddy ST, Yekta B, Hough G, Chanslor S, Anantharamaiah GM, and Fogelman AM (2010) L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation. Arterioscler Thromb Vasc Biol 30:283-289.
8. Cavelier C, Lorenzi I, Rohrer L, and von Eckardstein A (2006) Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. Biochim Biophys Acta 1761:655-666.
9. Davidson WS, Lund-Katz S, Johnson WJ, Anantharamaiah GM, Palgunachari MN, Segrest JP, Rothblat GH, and Phillips MC (1994) The influence of apolipoprotein structure on the efflux of cellular free cholesterol to high density lipoprotein. J Biol Chem 269:22975-22982.
10. deGoma EM, deGoma RL, and Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51:2199-2211.
11. Duffy D and Rader DJ (2006) Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113:1140-1150.
12. Duong PT, Weibel GL, Lund-Katz S, Rothblat GH, and Phillips MC (2008) Characterization and properties of pre-β-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I. J Lipid Res 49:1006-1014.
13. Folch J, Lees M, and Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509.
14. Garcia RA (2008) Pharmacological therapies for raising HDL cholesterol beyond synthetic small molecules. Curr Opin Investig Drugs 9:274-280.
15. Jonas A (1986) Reconstitution of high-density lipoproteins. Methods Enzymol 128:553-582.
16. Kawashiri MA, Zhang Y, Puré E, and Rader DJ (2002) Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice. Atherosclerosis 165:15-22. (Pubitemid 35223163)
17. Liu L, Bortnick AE, Nickel M, Dhanasekaran P, Subbaiah PV, Lund-Katz S, Rothblat GH, and Phillips MC (2003) Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: formation of nascent high density lipoprotein particles. J Biol Chem 278:42976-42984.
18. Matsuura F, Wang N, Chen W, Jiang XC, and Tall AR (2006) HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 116:1435-1442.
19. Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, Krozowski Z, Bukrinsky M, and Sviridov D (2008) Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo. J Lipid Res 49:2312-2322.
20. Mukhamedova N, Fu Y, Bukrinsky M, Remaley AT, and Sviridov D (2007) The role of different regions of ATP-binding cassette transporter A1 in cholesterol efflux. Biochemistry 46:9388-9398.
21. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP, Remaley AT, Sviridov D, and Chin-Dusting J (2008) High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28:2071-2077.
22. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, and Miller NE (1996) Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 16:1203-1214.
23. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, et al. (2004) Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109:3215-3220.
24. Nissen SE (2005) Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 96:61F-68F.
25. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 290:2292-2300.
26. Ostlund RE Jr and Matthews DE (1993) [13C]cholesterol as a tracer for studies of cholesterol metabolism in humans. J Lipid Res 34:1825-1831.
27. Remaley AT, Amar M, and Sviridov D (2008) HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. Expert Rev Cardiovasc Ther 6:1203-1215.
28. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, et al. (2001) Apolipoprotein specificity for lipid efflux by the human ABCAI transporter. Biochem Biophys Res Commun 280:818-823.
29. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, et al. (2003) Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 44:828-836.
30. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, and Rothblat GH (2009) Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol efflux. J Lipid Res 50:275-284.
31. Sethi AA, Amar M, Shamburek RD, and Remaley AT (2007) Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 8:201-212. (Pubitemid 46438455)
32. Sethi AA, Stonik JA, Thomas F, Demosky SJ, Amar M, Neufeld E, Brewer HB, Davidson WS, D'Souza W, Sviridov D, et al. (2008) Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J Biol Chem 283:32273-32282.
33. Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G, Kontush A, Jerome WG, Rye KA, and Davidson WS (2008) Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci USA 105:12176-12181.
34. Tabet F, Remaley AT, Segaliny AI, Millet J, Yan L, Nakhla S, Barter PJ, Rye KA, and Lambert G (2010) The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler Thromb Vasc Biol 30:246-252.
35. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, et al. (2007) Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 297:1675-1682.
36. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, et al. (2008) Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49:2302-2311.
37. Vaughan AM and Oram JF (2003) ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res 44:1373-1380.
38. Wool GD, Vaisar T, Reardon CA, and Getz GS (2009) An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and antiinflammatory ability than the 4F peptide. J Lipid Res 50:1889-1900.
39. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, and Rothblat GH (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:712-719.
40. Yvan-Charvet L, Wang N, and Tall AR (2010) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 30:139-143.